Pfizer PFE Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pfizer in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pfizer's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pfizer's royalty — revenue?
- Pfizer (PFE) reported royalty — revenue of $396M in Q1 2026.
- How has Pfizer's royalty — revenue changed year-over-year?
- Pfizer's royalty — revenue increased by 28.6% year-over-year, from $308M to $396M.
- What is the long-term trend for Pfizer's royalty — revenue?
- Over 3 years (2022 to 2025), Pfizer's royalty — revenue has grown at a 25.0% compound annual growth rate (CAGR), from $845M to $1.65B.
- What does royalty — revenue mean?
- Revenue earned from licensing the company's patents and intellectual property to other organizations.
- How do you interpret royalty — revenue?
- An increase suggests successful monetization of intellectual property and strong patent portfolio value, while a decrease may indicate patent expirations or reduced licensing activity.
- How does royalty — revenue compare across companies?
- Comparable to licensing and royalty income reported by other large-cap pharmaceutical and biotechnology firms that leverage their R&D output through external partnerships.